Tom Randall on Muck Rack

Tom Randall

New York
As seen in: Endpoints News, UOL Economia, Dailymotion, Medium, MSN, The New York Times, UOL, Bloomberg Businessweek, Bloomberg Markets Magazine, Bloomberg News, Estadão and
Head of Signal—biopharma intelligence at FT's @endpts. Former Bloomberg & still keeping tabs on future of energy+transport. Opinions are, too often, my own.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Tom

Contact Tom, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Biopharma Sentiment Index | Q2 2026

|
By Tom Randall
| Endpoints News
The latest BPSI shows significant improvements in biopharma conditions but raises questions about what comes next. Biopharma’s mood isn’t just running on hopes anymore. The Biopharma Sentiment Index took another step forward in Q2. The headline sentiment score climbed to 96, up from 90 in Q1 and 78 in Q4 2025. Industry sentiment is now within striking distance of the neutral (100) line for the first time since the four-year downturn that followed the pandemic.
Open in Who Shared Issue with article?

Biotech stocks are on a tear again: Signal insights

|
By Tom Randall
| Endpoints News
The XBI is up 30% in six months, beating the S&P 500 by 24 percentage points — and the gap only widened in April. Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Open in Who Shared Issue with article?

Take the Biopharma Sentiment Index survey for Q2 2026

|
By Tom Randall
| Endpoints News
This year is pivotal for biopharma, and we need your perspective on where things are going. Take the survey here. Endpoints is fielding the next Biopharma Sentiment Index (BPSI) — a concise, three-minute survey that distills thousands of industry views into a clear quarterly benchmark. The BPSI is one of the most direct snapshots of how people inside biopharma view the road ahead. More than 1,000 industry insiders took part in the BPSI last quarter.
Open in Who Shared Issue with article?
See all 1,125 licensed articles (1,503 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Tom

Contact Tom, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified